FY2024 EPS Estimate for Aura Biosciences Boosted by Analyst

Aura Biosciences, Inc. (NASDAQ:AURA) – HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Aura Biosciences in a research note issued on Wednesday, November 13th. HC Wainwright analyst E. White now anticipates that the company will earn ($1.69) per share for the year, up from their prior estimate of ($1.71). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.45) EPS, FY2025 earnings at ($1.94) EPS and FY2026 earnings at ($2.06) EPS.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02.

Several other research firms have also issued reports on AURA. JMP Securities upped their target price on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Scotiabank boosted their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Finally, Cowen restated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $9.14 on Monday. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The firm has a 50-day moving average price of $9.82 and a two-hundred day moving average price of $8.54. The firm has a market cap of $456.54 million, a price-to-earnings ratio of -5.28 and a beta of 0.33.

Insider Buying and Selling at Aura Biosciences

In other news, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares of the company’s stock, valued at $1,193,150.20. The trade was a 5.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Janet Jill Hopkins sold 11,822 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the completion of the transaction, the insider now directly owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 79,081 shares of company stock worth $891,353 over the last ninety days. 5.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aura Biosciences

Several hedge funds have recently made changes to their positions in AURA. American Century Companies Inc. purchased a new stake in Aura Biosciences during the 2nd quarter worth about $119,000. American International Group Inc. increased its position in shares of Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after buying an additional 3,782 shares during the period. Virtu Financial LLC purchased a new stake in shares of Aura Biosciences in the first quarter worth about $144,000. SG Americas Securities LLC bought a new position in shares of Aura Biosciences in the third quarter valued at approximately $169,000. Finally, Rhumbline Advisers grew its stake in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares in the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.